Tetraphase Pharmaceuticals Inc. (TTPH) Upgraded at Zacks Investment Research
Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage currently has a $4.25 price target on the biopharmaceutical company’s stock. Zacks Investment Research’s target price would suggest a potential upside of 13.03% from the stock’s current price.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
Separately, Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Monday, June 20th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $9.15.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down 3.46% on Tuesday, reaching $3.63. The company’s stock had a trading volume of 140,213 shares. Tetraphase Pharmaceuticals has a 52-week low of $3.12 and a 52-week high of $12.45. The firm’s 50-day moving average price is $3.82 and its 200 day moving average price is $4.27. The company’s market cap is $133.21 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by $0.01. Tetraphase Pharmaceuticals had a negative net margin of 821.25% and a negative return on equity of 35.43%. The company earned $1.20 million during the quarter, compared to the consensus estimate of $2.05 million. During the same quarter last year, the firm posted ($0.72) EPS. The company’s quarterly revenue was down 63.6% on a year-over-year basis. Equities analysts anticipate that Tetraphase Pharmaceuticals will post ($1.98) EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of TTPH. Bridgeway Capital Management Inc. purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth $1,555,000. BlackRock Fund Advisors increased its position in Tetraphase Pharmaceuticals by 7.2% in the second quarter. BlackRock Fund Advisors now owns 1,432,702 shares of the biopharmaceutical company’s stock worth $6,161,000 after buying an additional 96,291 shares during the period. Candriam Luxembourg S.C.A. increased its position in Tetraphase Pharmaceuticals by 31.7% in the second quarter. Candriam Luxembourg S.C.A. now owns 374,000 shares of the biopharmaceutical company’s stock worth $1,608,000 after buying an additional 90,000 shares during the period. Emerald Acquisition Ltd. purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth $318,000. Finally, Gabelli Funds LLC increased its position in Tetraphase Pharmaceuticals by 103.4% in the second quarter. Gabelli Funds LLC now owns 120,000 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 61,000 shares during the period. 59.41% of the stock is currently owned by institutional investors and hedge funds.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.
Receive News & Stock Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.